Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last SFr.25.80 CHF
Change Today +0.20 / 0.78%
Volume 8.1K
NWRN On Other Exchanges
SIX Swiss Ex
As of 11:43 AM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

newron pharmaceuticals spa (NWRN) Snapshot

Previous Close
Day High
Day Low
52 Week High
03/3/15 - SFr.35.85
52 Week Low
10/16/14 - SFr.14.35
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

newron pharmaceuticals spa (NWRN) Related Businessweek News

No Related Businessweek News Found

newron pharmaceuticals spa (NWRN) Details

Newron Pharmaceuticals S.p.A., a biopharmaceutical company, focuses on the discovery and development of drugs for the treatment of central nervous system disorders and pain in Italy. It offers safinamide for the treatment of patients with idiopathic Parkinson’s disease. The company also has a pipeline of novel drug candidates in Phase II trials, which include Sarizotan for patients with Rett syndrome; sNN0031 for the treatment of Parkinson’s disease patients who are no longer responding to oral therapy; and sNN0029 for the treatment of patients with amyotrophic lateral sclerosis. In addition, it develops NW-3509, first add-on therapy that has completed Phase I clinical trials for the treatment of schizophrenia; and Ralfinamide for the treatment of neuropathic pain. The company was founded in 1998 and is headquartered in Bresso, Italy.

23 Employees
Last Reported Date: 03/4/15
Founded in 1998

newron pharmaceuticals spa (NWRN) Top Compensated Officers

Chief Executive Officer and Executive Directo...
Total Annual Compensation: €409.0K
Chief Medical Officer
Total Annual Compensation: €879.0K
Compensation as of Fiscal Year 2014.

newron pharmaceuticals spa (NWRN) Key Developments

Zambon and Newron Pharmaceuticals Launch Xadago® (safinamide) for Patients with Mid to Late-Stage Parkinson’s Disease in Germany

Zambon S.p.A. and its partner Newron Pharmaceuticals S.p.A. announced the launch of Xadago® (safinamide) in Germany for the treatment of mid- to late-stage Parkinson's disease (PD). Germany is the first country in which Xadago®, which has been approved as add-on therapy to a stable dose of levodopa (L-dopa) alone or in combination with other PD therapies for mid-to late-stage fluctuating patients, is launched.

Newron Pharmaceuticals S.p.A. Presents at BioEquity Europe 2015, May-19-2015 through May-20-2015

Newron Pharmaceuticals S.p.A. Presents at BioEquity Europe 2015, May-19-2015 through May-20-2015. Venue: InterContinental Vienna, Vienna, Austria. Presentation Date & Speakers: May-20-2015, Stefan Weber, Chief Executive Officer and Executive Director.

Newron Pharmaceuticals S.p.A. Announces Earnings Results for the Year Ended December 31, 2014

Newron Pharmaceuticals S.p.A. announced earnings results for the year ended December 31, 2014. For the period, the company reported licence income of €1,300,000 against €3,213,000 a year ago. Net loss was €10.1 million, compared to €7.1 million a year ago. Loss per share was €0.80 against €0.62 a year ago. Operating loss was €11.22 million against €7.8 million a year ago. The net loss was due to lower license income and increased investment into R&D projects.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NWRN:SW SFr.25.80 CHF +0.20

NWRN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NWRN.
View Industry Companies

Industry Analysis


Industry Average

Valuation NWRN Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 194.2x
Price/Book 10.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 191.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NEWRON PHARMACEUTICALS SPA, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at